2nd quarter global revenue of CHF342 1,000,000, which equates to about US380 $1,000,000 was achieved, earning royalty revenue of $37,000,000 for PTC. As Matt mentioned, the 2nd quarter performance puts us in a strong position to achieve 2023 total revenue guidance of $940,000,000 to $1,000,000,000 including an expected $100,000,000 milestone when average D surpasses $1,500,000,000 in annual revenue. Non GAAP R and D expenses were $170,000,000 for the Q2 of 2023, excluding $16,000,000 in non cash stock based compensation expense, compared to $143,000,000 for the Q2 of 2022, excluding $14,000,000 in non cash stock based comp expense. The year over year increase in R and D expenses reflects additional investments in advancement of the clinical pipeline. Non GAAP SG and A expenses were $75,000,000 for the Q2 of 2023, excluding $14,000,000 in non cash stock based compensation expense, compared to $66,000,000 for the Q2 of 2022, excluding $14,000,000 in non cash stock based compensation expense.